GlobeImmune, Inc.
GBIMOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$575
P/E Ratio—
52W High$0.0005
52W Low$0.000001
GlobeImmune, Inc. (GBIM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GBIM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2015-12 | 2014-12 | 2013-12 | 2012-12 | 2011-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $6.46M | $5.97M | $22.52M | $14.64M | $5.11M |
| Cost of Revenue | $2.65M | $4.99M | $9.02M | $0.01M | $0.00M |
| Gross Profit | $3.81M | $0.97M | $13.49M | $14.63M | $5.11M |
| Gross Margin %(computed) | 58.99% | 16.33% | 59.92% | 99.93% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $4.48M | $7.21M | $10.88M | $11.73M | $12.06M |
| G&A Expenses | $4.55M | $4.28M | $3.17M | $5.95M | $0.00M |
| Total Operating Expenses | $9.22M | $11.79M | $14.83M | $18.61M | $17.70M |
| Operating Income | ($2.77M) | ($5.82M) | $7.69M | ($3.97M) | ($12.59M) |
| Operating Margin %(computed) | -42.85% | -97.53% | 34.14% | -27.09% | -246.55% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $3.89M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($2.77M) | ($16.26M) | $9.59M | ($2.01M) | ($13.73M) |
| Income Tax Expense | $0.00M | $3.89M | $0.12M | $0.00M | $1.13M |
| Net Income | ($2.77M) | ($20.15M) | $9.48M | ($2.01M) | ($14.86M) |
| Net Margin %(computed) | -42.85% | -337.75% | 42.08% | -13.76% | -290.87% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.48 | $-6.91 | $-35.64 | $-21.07 | $-155.37 |
| Wtd Avg Shares | 5.75M | 2.91M | 0.10M | 0.10M | 0.10M |
| EBITDA | ($2.58M) | ($12.08M) | $8.46M | ($1.09M) | ($12.77M) |
| EBITDA Margin %(computed) | -39.95% | -202.39% | 37.56% | -7.44% | -250.06% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more GlobeImmune, Inc. data
About GlobeImmune, Inc. (GBIM) Income Statement
GlobeImmune, Inc. (GBIM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2015, GBIM reported revenue of $0.01B, gross profit of $0.00B (gross margin 58.99%), and net income of ($0.00B) — a net profit margin of -42.85%.
Frequently asked questions
GBIM · 4 questionsGlobeImmune, Inc. (GBIM) reported revenue of $0.01B for 2015, up 8.2% year-over-year.
GBIM revenueGBIM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08